Fig. 1.

Overall survival rate after recurrence (A) and after stopping CDK4/6 inhibitors (B). Group A: exemestane plus everolimus (black line), group B: endocrine monotherapy (red line), group C: chemotherapy (green line). Survival rate was estimated by using the Kaplan-Meier method and compared by using the log-rank test. Symbols indicate censored data. The median OS was 161.1 months in groups A and C and 71.7 months in group B. The median OS after stopping CDK4/6 inhibitors was 34.5 months in group A, 13.6 months in group B, and 19.5 months in group C.